Phathom Pharmaceuticals, Inc. (PHAT)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$9.50+4.97%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Broken: Primary pillar broken — Full year 2026 revenue between $320M and $345M: FY26 rev guide $310M-$325M vs $320M-$345M target.
Phathom aims to make a profit starting Q3 2026. Revenue should reach about $320-$345 million in 2026. Gross margin is expected near 80% for the year. The company showed progress with operating income improving from -$59M to -$15M.
Phathom is still losing money and faces legal challenges. Revenue growth may slow or miss targets. Profit margins could weaken if costs rise. The company depends on clinical trial success and regulatory approval.
The market expects about 92% revenue growth next year. Our fair value is near $30.57, reflecting optimism but risks remain. We see valuation cheap versus peers but earnings remain negative.
Breaks if: Gross margin falls below 75% in FY26
Maintain gross margin around 80% for the full year 2026 as part of financial performance goals.
Stated as a priority in 3 of last 3 quarters. Gross margin approximated 79.4% in 2026-Q1 and 79.7% in 2026-Q2, close to the 80% target. Management maintained guidance for approximately 80% gross margin for full year 2026. The trajectory is delivering consistent gross margin near the stated goal.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The company is currently loss-making but is focused on achieving profitability and maintaining revenue growth, which could lead to a positive shift in its long-term thesis.
The market seems to have priced in a justified valuation, reflecting a low fragility tier. There is an expectations gap, indicating that investors may not fully anticipate the potential for improved performance in the near future.
Management is working towards achieving operating profitability and maintaining revenue guidance, with recent performance showing strong revenue growth. However, the company remains loss-making, and the risk is elevated due to potential economic factors affecting the sector.
The thesis hinges on whether PHAT can reverse its recent guidance cuts and improve its financial outlook. Additionally, the performance of sector leaders and overall economic conditions, such as job growth, will play a crucial role in shaping the company's trajectory.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. The latest earnings report missed expectations. This miss raises concerns about future performance. There are no new supports to offset this threat.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Phathom continues to expect gross margin of approximately 80% for 2026.”
“Gross margin of approximately 80% expected for full year 2026.”
“Gross margin of approximately 80% expected for full year 2026.”
Breaks if: Operating income remains below $0 past Q3 2026
Breaks if: Revenue falls below $320M in FY26
Overall, PHAT's long-term thesis is intact, supported by strong revenue growth and sector momentum, but it faces challenges in achieving profitability. Not investment advice.